RB in discussions with Merck

RNS Number : 6987F

Reckitt Benckiser Group PLC

28 April 2014

 



28 April 2014

Following press speculation, RB confirms that it is in discussions with Merck regarding an offer for its consumer health business. We understand that we are part of a competitive process. There is absolutely no certainty as to the outcome or timing of this process.

A further announcement will be made, if appropriate, in due course.

For further information, please contact:

Reckitt Benckiser Richard Joyce Director, Investor Relations Andraea Dawson-Shepherd SVP, Global Corporate Communication & Affairs	[phone]
Brunswick (Financial PR) David Litterick	[phone]

Cautionary note concerning forward-looking statements

This document contains statements with respect to the financial condition, results of operations and business of RB and certain of the plans and objectives of the Group with respect to these items.  These forward-looking statements are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995.  In particular, all statements that express forecasts, expectations and projections with respect to future matters, including trends in results of operations, margins, growth rates, overall market trends, the impact of interest or exchange rates, the availability of financing to the Company, anticipated cost savings or synergies and the completion of strategic transactions are forward-looking statements.  By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future.  There are a number of factors discussed in this report, that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including many factors outside Reckitt Benckiser's control.  Past performance cannot be relied upon as a guide to future performance.

 

END

 

 

OFFPGUGUCUPCGQR